Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration: One-Year Findings from the IVAN Randomized Trial

IVAN Study Investigators, Usha Chakravarthy, Simon P Harding, Chris A Rogers, Susan M Downes, Andrew J Lotery, Sarah Wordsworth

Research output: Contribution to journalArticle (Academic Journal)peer-review

614 Citations (Scopus)

Abstract

To compare the efficacy and safety of ranibizumab and bevacizumab intravitreal injections to treat neovascular age-related macular degeneration (nAMD).
Original languageEnglish
Pages (from-to)1399-1411
Number of pages13
JournalOphthalmology
Volume119
Issue number7
Early online date10 May 2012
DOIs
Publication statusPublished - Jul 2012

Bibliographical note

Copyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Structured keywords

  • BTC (Bristol Trials Centre)
  • Centre for Surgical Research

Keywords

  • Vascular Endothelial Growth Factor A
  • Reading
  • Contrast Sensitivity
  • Humans
  • Fluorescein Angiography
  • Aged
  • Quality of Life
  • Wet Macular Degeneration
  • Angiogenesis Inhibitors
  • Intravitreal Injections
  • Drug Costs
  • Cost of Illness
  • Treatment Outcome
  • Middle Aged
  • Antibodies, Monoclonal, Humanized
  • Visual Acuity
  • Female
  • Male

Fingerprint

Dive into the research topics of 'Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration: One-Year Findings from the IVAN Randomized Trial'. Together they form a unique fingerprint.

Cite this